SMU-037 是一种口服有效的选择性 ROS1 抑制剂,作用强效(IC₅₀ = 6.8 nM)且能穿透血脑屏障,对 ALK 的选择性约为 25 倍,并对 G2032R 耐药突变表现出卓越的敏感性,可通过抑制 ROS1 及其下游 MAPK-ERK 信号通路的磷酸化引起细胞周期阻滞与细胞凋亡 (apoptosis),在皮下移植瘤和颅内转移瘤小鼠模型中均能抑制肿瘤生长,可用于非小细胞肺癌 (NSCLC) 的相关研究。
SMU-037
产品编号: MS-Y15620 分子式: C29H29ClF2N4O 分子量: 523.02
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

SMU-037 是一种口服有效的选择性 ROS1 抑制剂,作用强效(IC₅₀ = 6.8 nM)且能穿透血脑屏障,对 ALK 的选择性约为 25 倍,并对 G2032R 耐药突变表现出卓越的敏感性,可通过抑制 ROS1 及其下游 MAPK-ERK 信号通路的磷酸化引起细胞周期阻滞与细胞凋亡 (apoptosis),在皮下移植瘤和颅内转移瘤小鼠模型中均能抑制肿瘤生长,可用于非小细胞肺癌 (NSCLC) 的相关研究。

生物实验数据

生物活性 SMU-037 is an orally active and potent selective ROS1 inhibitor (IC₅₀ = 6.8 nM) that penetrates the blood-brain barrier, exhibits approximately 25-fold selectivity over ALK, and demonstrates excellent sensitivity to the G2032R resistance mutation; it inhibits the phosphorylation of ROS1 and its downstream MAPK-ERK signaling pathway, thereby inducing cell cycle arrest and apoptosis, suppresses tumor growth in both subcutaneous xenograft and intracranial metastasis mouse models, and can be used for research related to non-small cell lung cancer (NSCLC).
体外研究
(In Vitro)

SMU-037 (compound 9y) 对 A549 (IC50 = 0.9 μM)、HCC-78 (IC50 = 1.1 μM) 和 NCI-H3122 (IC50 = 1.1 μM) 细胞均表现出显著的活性,并且对 Ba/F3 ROS1G2032R 和 Ba/F3 ROS1L2026R 细胞的抑制作用也十分显著,IC50 值分别为 8.9 nM 和 32.0 nM。
SMU-037 (0.001-3 μM,8 小时) 能以剂量依赖的方式减弱多种 Ba/F3 和 A549 细胞中 ROS1 及其下游关键信号通路 MAPK-ERK 的磷酸化。
SMU-037 (0-100 nM,48 小时) 可引起细胞周期阻滞 (在 ROS1WT 细胞中阻滞于 G0/G1 期,在 ROS1G2032R 细胞中阻滞于 G2/M 期),并诱导 Ba/F3-ROS1WT 和 Ba/F3-ROS1G2032R 细胞凋亡。

Western Blot Analysis

Cell Line: Ba/F3-ROS1WT, Ba/F3-ROS1G2032R, Ba/F3-ROS1L2026M and A549-ROS1G2032R cells
Concentration: 1, 10, 100, and 10000 nM, 0.1, 0.3, 1 and 3 μM
Incubation Time: 8 h
Result: Exhibited remarkable inhibitory effects on ROS1G2032R phosphorylation at the concentration of 1000 nM.
Slightly inhibited the downstream MAPK-ERK signaling pathway at the concentration of 1000 nM, with efficacy comparable to Cabozantinib (MS-Q41776).
Led to attenuated phosphorylation of ROS1 and the key downstream MAPK-ERK signaling pathway in a dose-dependent manner in Ba/F3-ROS1WT and Ba/F3-ROS1L2026M cells, comparable to Crizotinib (MS-B27157).
Exhibited a marked suppression of ROS1 phosphorylation at a concentration of 1 μM in A549-ROS1G2032R cells.

Cell Cycle Analysis

Cell Line: Ba/F3-ROS1WT and Ba/F3-ROS1G2032R cells
Concentration: 0, 10, 30, and 100 nM
Incubation Time: 48 h
Result: Significantly increased the percentage of ROS1WT cells in the G0/G1 phase.
Caused a predominant G2/M phase accumulation in ROS1G2032R cells.
The G0/G1 phase of ROS1G2032R cells increased from 57.10% (control) to 60.71%, 72.97%, and 85.28%, respectively.
The G2/M phase of ROS1G2032R cells increased from 6.14% (control) to 6.98%, 14.42%, and 27.16%, respectively.

Apoptosis Analysis

Cell Line: Ba/F3-ROS1WT and Ba/F3-ROS1G2032R cells
Concentration: 0, 10, 30, and 100 nM
Incubation Time: 48 h
Result: Induced a dose-dependent increase in apoptosis.
Apoptotic rates in ROS1WT cells rose from 13.12% (control) to 16.95%, 31.50%, and 91.87%.
Apoptotic rates in ROS1G2032R cells increased from 19.85% (control) to 20.46%, 28.03%, and 54.60%.
体内研究
(In Vivo)

SMU-037 (15、30 和 60 mg/kg,灌胃,每日一次,持续 14 天) 在异种移植和脑转移小鼠模型中显示出强大的肿瘤生长抑制作用。

Animal Model: Male Balb/c nude mice (16-20 g) injected with Ba/F3 CD74-ROS1G2032R cells
Dosage: 15, 30 and 60 mg/kg
Administration: i.g., q.d. for 14 days
Result: Effectively suppressed Ba/F3 tumor growth in a dose-dependent manner, with tumor growth inhibition (TGI) values of 118, 140, and 156%, respectively.
Showed no significant body weight reduction and no morphological changes or side effects in heart, liver and kidney.
Significantly inhibited ROS1 phosphorylation in tumor tissue, demonstrating its on-target effect in vivo.
Induced prominent alterations in the morphological characteristics of tumor cells, including cellular contraction, agglutination, and marginalization of nuclear chromatin.
Significantly reduced expression level of the Ki-67 protein, indicating strong anti-proliferative activity.
Animal Model: Male Balb/c nude mice (16-20 g) injected with A549-ROS1G2032R cells
Dosage: 15, 30 and 60 mg/kg
Administration: i.g., q.d. for 14 days
Result: Demonstrated significant tumor regression at doses of 30 mg/kg and 60 mg/kg, comparable to the positive control Lorlatinib (MS-U83680, 30 mg/kg).
Animal Model: Male Balb/c nude mice (16-20 g) injected with luciferase-transduced A549-ROS1G2032R cells
Dosage: 30 and 60 mg/kg
Administration: i.g., q.d. for 14 days
Result: Prominently reduced tumor load (as measured using photon flux) in the brain without obvious body weight loss.
Could penetrate blood-brain barrier.

化学信息

分子量 523.02
分子式 C29H29ClF2N4O

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础